A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines  

作　　者：Taku A.Tokuyasu Jian-Dong Huang 

机构地区：[1]Institute of Synthetic Biology,Shenzhen In stitutes of Advanced Technology,Chinese Academy of Sciences,Shenzhen 518055,Guangdong,China [2]School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong,China [3]Shenzhen Institute of Research and Innovation,University of Hong Kong,Hong Kong,China

出　　处：《Journal of Cancer Metastasis and Treatment》2018年第1期10-33,共24页癌症转移与治疗（英文版）

基　　金：This work was supported by a National Basic Research Program of China(973 Program,No.2014CB745202);the Shenzhen Peacock Team Project(No.KQTD2015033117210153);the Shenzhen Science and Technology Innovation Committee Basic Science Research Grants(No.JCYJ20170413154523577,No.JCYJ20150629151046896);the Guangdong Natural Science Funds for Distinguished Young Scholar Grant(No.S2013050016987).

摘　　要：Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients.Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective,even in previously refractory late stage disease.Such developments,together with advances in technology,have strongly encouraged revisiting the concept of neoantigen vaccines.Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments,grasp current issues,and contribute to further progress.

关 键 词：IMMUNOTHERAPY cancer vaccine IMMUNOINFORMATICS precision medicine combination therapy theoretical models systems biology 

分 类 号：R73[医药卫生—肿瘤]